A genetic screen to identify genes that rescue the slow growth phenotype of c-myc null fibroblasts

[1]  J F Barrett,et al.  Identification of CDK4 as a target of c-MYC. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  W. Ansorge,et al.  Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27 , 1999, The EMBO journal.

[3]  K. Helin,et al.  CDC25A Phosphatase Is a Target of E2F and Is Required for Efficient E2F-Induced S Phase , 1999, Molecular and Cellular Biology.

[4]  John M. Sedivy,et al.  c-Myc Regulates Cyclin D-Cdk4 and -Cdk6 Activity but Affects Cell Cycle Progression at Multiple Independent Points , 1999, Molecular and Cellular Biology.

[5]  J. Sedivy,et al.  Transactivation-defective c-MycS retains the ability to regulate proliferation and apoptosis. , 1998, Genes & development.

[6]  M. Cole,et al.  c-myc null cells misregulate cad and gadd45 but not other proposed c-Myc targets. , 1998, Genes & development.

[7]  J. Sedivy,et al.  Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[8]  C. Dang,et al.  Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene , 1997, Molecular and cellular biology.

[9]  R. Bernards,et al.  Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity , 1997, Oncogene.

[10]  A. Fornace,et al.  Myc represses the growth arrest gene gadd45 , 1997, Oncogene.

[11]  Andreas Sewing,et al.  Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27Kip1 binding to newly formed complexes , 1997, Oncogene.

[12]  D. Beach,et al.  Cdc25 cell-cycle phosphatase as a target of c-myc , 1996, Nature.

[13]  R. Eisenman,et al.  Myc‐Max heterodimers activate a DEAD box gene and interact with multiple E box‐related sites in vivo. , 1996, The EMBO journal.

[14]  I. Rosenwald,et al.  Upregulated expression of the genes encoding translation initiation factors eIF-4E and eIF-2alpha in transformed cells. , 1996, Cancer letters.

[15]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[16]  P. Farnham,et al.  An E-box-mediated increase in cad transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants , 1995, Molecular and cellular biology.

[17]  R. DePinho,et al.  Inhibition of ras-induced proliferation and cellular transformation by p16INK4 , 1995, Science.

[18]  G. Prendergast,et al.  c‐Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. , 1994, The EMBO journal.

[19]  J L Cleveland,et al.  The ornithine decarboxylase gene is a transcriptional target of c-Myc. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[20]  V. Rotter,et al.  c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[21]  S. Epstein,et al.  Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Eisenman,et al.  Myc and Max proteins possess distinct transcriptional activities , 1992, Nature.

[23]  R. Ralston.  Complementation of transforming domains in E1a/myc chimaeras , 1991, Nature.

[24]  J. Bishop,et al.  The MYC protein activates transcription of the alpha‐prothymosin gene. , 1991, The EMBO journal.

[25]  J. Barrett,et al.  An amino-terminal c-myc domain required for neoplastic transformation activates transcription , 1990, Molecular and cellular biology.

[26]  H. Land,et al.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. , 1990, Nucleic acids research.

[27]  P. Yaciuk,et al.  TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains , 1990, Cell.

[28]  L. Penn,et al.  Negative autoregulation of c‐myc transcription. , 1990, The EMBO journal.

[29]  E. Prochownik,et al.  c-myc antisense transcripts accelerate differentiation and inhibit G1 progression in murine erythroleukemia cells , 1988, Molecular and cellular biology.

[30]  H. Varmus,et al.  Definition of regions in human c-myc that are involved in transformation and nuclear localization , 1987, Molecular and cellular biology.

[31]  R. Weinberg,et al.  N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma , 1986, Cell.

[32]  A. Kimchi,et al.  Close link between reduction of c-myc expression by interferon and G0/G1 arrest , 1985, Nature.

[33]  P. Leder,et al.  Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor , 1983, Cell.

[34]  M. Henriksson,et al.  Proteins of the Myc network: essential regulators of cell growth and differentiation. , 1996, Advances in cancer research.

[35]  Eric Wickstrom,et al.  A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1 , 1987, Nature.